Today, the FDA and CDC confirmed a 13-state investigation into Main Street Family Pharmacy in Newbern, Tennessee, a compounding pharmacy, regarding a particular steroid injection, methylprednisolone, used specifically as an injectable anti-inflammatory. Logan Primary Care, at our Herrin location, received and administered this drug to patients between December 6, 2012, and April 24, 2013.
On April 24, 2013, Logan Primary discovered the development of a sterile abscess at the injection site of one of our patients was not an isolated incident. On rare occasion, a sterile abscess is a known side effect. To date, we have confirmed five patients developed sterile abscesses at the injection site. These five patients have undergone follow up.
Upon discovery that this was not an isolated incident, we immediately ceased administering these methylprednisolone injections, and removed the product from utilization. We began a rigorous internal review in cooperation with Bi-County Health, the Illinois Department of Public Health and FDA. This week, the FDA took samples of the medication for appropriate testing. We have NOT received the results of that analysis as of yet. We are also conducting our own laboratory testing.
Again, at this time, only five patients have been identified locally in what the FDA calls “Adverse Drug Events” related to this injection. We are, out of an abundance of caution, personally contacting approximately 2,000 patients that received a methylprednisolone injection in both our Herrin and West Frankfort clinics between December 6, 2012, and April 24, 2013. We have already started that process.
Patients should look for:
- Pain or swelling at the injection site
- A painful lump under the surface of the skin at the injection site
If any of those symptoms are present, we urge patients to contact their primary care physician and seek medical attention. For additional questions, contact our patient relations department at (618) 457-5200, extension 67102.